Antiproliferative activity of topotecan and SN-38, alone or in combination with NiK-12192, on drug-sensitive and drug-resistant colon cancer cell lines
Cell Line | IC50a | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| NiK-12192 | Topotecan | Topotecan + NiK-12192b | SN-38 | SN-38 + NiK-12192b | |||||
| μM | |||||||||
| HT29 | 1.06 | 0.3 | 0.05 | 0.03 | 0.01 | ||||
| HT29/Mit | 1.09 | 30 | 8 | 0.44 | 0.31 | ||||
| LoVo | 2.51 | 13.3 | 4 | 0.06 | 0.002 | ||||
| LoVo/DX | 3.12 | 17 | 10 | 0.15 | 0.05 | ||||
↵ a The IC50 was evaluated after 72 h of drug exposure, by sulforodamine B assay. Data represent the mean values of three independent experiments. Standard errors were lower than the 7% of each value.
↵ b NiK-12192 was used at subtoxic conditions: 0.5 μM in HT29 and HT29/Mit cells and 1 μM in LoVo and LoVo/DX cells.